Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FRA: 3QP) has entered the mobile diagnostics space by launching a direct-to-consumer diabetes screening tool. The firm has chosen India as the platform’s first market. The non-invasive solution provides fast risk assessments via smartphones with no need for blood work or clinic visits.
By combining AI-driven facial and biometric technology with mobile delivery, Predictmedix AI makes it easier and more affordable for diabetes screening. The mobile diagnostics platform also easily scales across underserved populations in India.
The launch is a major leap in Predictmedix AI’s goal to drive mobile diagnostics adoption in global healthcare. It supports their broader push for preventive, AI-enabled screening across large populations.
“We are solving a critical healthcare gap with this mobile-first solution,” said Dr. Rahul Kushwah, COO of Predictmedix AI. “With more than 100 million diabetics in India, many undiagnosed, our app aims to close that gap using mobile diagnostics.”
Key Features Include:
- Smartphone-based, instant diabetic risk detection
- Facial and biometric analysis backed by proven AI
- Simple user interface with multilingual access
- Data privacy compliance under India’s DPDP Act
Strategic Importance:
India has a diabetes epidemic. One-third of adults may be diabetic or prediabetic by 2045. In contrast, smartphone adoption has grown over 1.1 billion users. That offers huge potential for mobile diagnostics solutions.
Predictmedix AI’s platform is set to:
- Tap into a rapidly expanding health tech market
- Drive revenue from both consumers and enterprise partners
- Support health goals of governments, NGOs, and corporates
- Expand globally through scalable, cloud-powered delivery
Explore More Cutting-Edge Tech Like This – Stay ahead of the game. Visit IT Tech News for more insights on AI, data tech, and innovation shaping our future.
News Source: Businesswire.com
